{"name":"Steve Yoelin M.D. Medical Associates, Inc.","slug":"steve-yoelin-m-d-medical-associates-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Hyper-Diluted Botox","genericName":"Hyper-Diluted Botox","slug":"hyper-diluted-botox","indication":"Investigational formulation; specific Phase 2 indications not publicly detailed","status":"phase_2"}]}],"pipeline":[{"name":"Hyper-Diluted Botox","genericName":"Hyper-Diluted Botox","slug":"hyper-diluted-botox","phase":"phase_2","mechanism":"Hyper-diluted botulinum toxin blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions, potentially at lower concentrations than standard Botox formulations.","indications":["Investigational formulation; specific Phase 2 indications not publicly detailed"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}